Physician profile
Joseph Murcko
NPI 1679102420
$1,484.20
in general payments reported to CMS, 2019-2025
18 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $428 · 2024: $706 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.10 | 2024-2025 | Breztri, Farxiga, Nexium |
| Amgen INC. | $187.29 | 2023-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $176.09 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.92 | 2023-2025 | Xifaxan |
| Abbvie INC. | $131.99 | 2023-2025 | |
| Glaxosmithkline, LLC. | $123.89 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $115.61 | 2023-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $47.52 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $47.10 | 2023-2024 | Verquvo |
| Pfizer INC. | $39.19 | 2024-2025 | |
| Astellas Pharma US INC | $37.34 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $36.44 | 2024 | |
| Paratek Pharmaceuticals, INC. | $33.11 | 2023 | Nuzyra |
| Exact Sciences Corporation | $29.27 | 2024 | Cologuard Collection Kit |
| Inari Medical, INC. | $26.86 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.10 | 2023 | Rexulti |
| Viatris Specialty LLC | $23.02 | 2025 | Yupelri |
| Corcept Therapeutics | $16.36 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Murcko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.